Patents Assigned to Hyogo
-
Publication number: 20240052345Abstract: The present invention provides novel antisense oligonucleotide pharmaceutical compositions having higher RNA aggregate-removing activity than conventional pharmaceutical compositions. The pharmaceutical composition of the present invention contains an oligonucleotide having any base sequence of a repeated sequence in which cytosine-adenine-guanine trinucleotides are repeated 5 to 13 times, from the 5? end to the 3? end, and the oligonucleotide has a mixmer structure containing at least two types of RNase H inactive nucleotide analogs. The present invention provides the pharmaceutical composition of the present invention used for the treatment of some symptoms of myotonic dystrophy type 1 disease.Type: ApplicationFiled: December 22, 2021Publication date: February 15, 2024Applicants: RIKEN, HYOGO COLLEGE OF MEDICINEInventors: Haruhisa INOUE, Mika SUGA, Takayuki KONDO, Takashi KIMURA
-
Patent number: 11899316Abstract: The present invention provides a polarization-independent terahertz wave control element, and provides a method for manufacturing a polarization-independent terahertz wave control element.Type: GrantFiled: December 25, 2020Date of Patent: February 13, 2024Assignees: NAGAOKA UNIVERSITY OF TECHNOLOGY, UNIVERSITY OF HYOGO, NISSAN CHEMICAL CORPORATIONInventors: Tomoyuki Sasaki, Hiroshi Ono, Nobuhiro Kawatsuki, Kohei Goto, Kimiaki Tsutsui
-
Publication number: 20240000853Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.Type: ApplicationFiled: July 20, 2023Publication date: January 4, 2024Applicants: HYOGO COLLEGE OF MEDICINE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Tomohiro MATSUYAMA, Takayuki NAKAGOMI, Yu FUKUDA
-
Patent number: 11858994Abstract: T cell receptor (TCR) diversity of a subject, including TCR diversity in CD8+ T cell subsets, is used as a predictive indicator of responsiveness of the subject to cancer immunotherapy prior to initiation of the immunotherapy. Exemplified immunotherapy comprises administering an immune checkpoint inhibitor to a subject, wherein a TCR diversity value in CD8+ T cell subsets from the subject, such as CD8+ T cell subpopulations defined by differential cell surface marker expression, is higher than a reference value.Type: GrantFiled: March 14, 2018Date of Patent: January 2, 2024Assignees: Repertoire Genesis Incorporation, Hyogo College of MedicineInventors: Seiji Matsumoto, Ryuji Suzuki
-
Publication number: 20230407112Abstract: A conductive paste composition includes: carbon black having a porous structure and having a DBP oil absorption amount of greater than 240 mL/100 g and a specific surface area of greater than 350 m2/g; and a liquid silicone rubber base composition, in which in a case where the conductive paste composition is dried and cured at 180° C. for two hours to form a conductive film, a content of the carbon black in the conductive film is 4% by mass or greater and 24% by mass or less, and a surface resistance of the conductive film is 1 k? or greater and 9 k? or less.Type: ApplicationFiled: October 15, 2021Publication date: December 21, 2023Applicants: Lion Specialty Chemicals Co., Ltd., University of HyogoInventors: Kasumi MUKAIDA, Hiromu SATO, Katsuyoshi OHARA, Akinori KANETANI, Kazusuke MAENAKA, Mai KONDO, Tokuji YOKOMATSU
-
Publication number: 20230297693Abstract: An information processing apparatus includes an input receiving unit, a first permutation processing unit that repeats a first permutation process a times and outputs a first intermediate text, a second permutation processing unit that repeats a second permutation process b times and outputs a second intermediate text, and a termination processing unit that performs a termination process for outputting a ciphertext by using the second intermediate text as an input. The first permutation process is a permutation process in which an addition process, an S-box process, a bit permutation process, and a matrix multiplication process are successively performed. The second permutation process is a permutation process in which the addition process, the S-box process, a nibble permutation process, and the matrix multiplication process are successively performed. The termination process is a permutation process in which the S-box process and the addition process are successively performed.Type: ApplicationFiled: September 2, 2020Publication date: September 21, 2023Applicants: NEC Corporation, UNIVERSITY OF HYOGOInventors: Kazuhiko MINEMATSU, Takanori ISOBE, Kosei SAKAMOTO
-
Patent number: 11692037Abstract: Postoperative adhesion formation at an invasion site and migration of neutrophils to the site of surgical invasion are suppressed by administering an anti-IL-6 receptor antibody and/or a neutrophil-neutralizing antibody.Type: GrantFiled: October 19, 2018Date of Patent: July 4, 2023Assignees: Hyogo College of Medicine, Chugai Seiyaku Kabushiki KaishaInventors: Jiro Fujimoto, Tomohiro Yoshimoto, Naoki Uyama
-
Patent number: 11644791Abstract: A holographic imaging device and method realizes both a transmission type and a reflection type, and also realizes a long working distance wide field of view or ultra-high resolution. Object light emitted from an object, sequentially illuminated with parallel illumination light whose incident direction is changed, is recorded on a plurality of object light holograms for each incident direction using off-axis spherical wave reference light. The reference light is recorded on a reference light hologram using in-line spherical wave reference light being in-line with the object light. An object light wave hologram and its spatial frequency spectrum at the object position are generated for each incident direction using each hologram. A synthetic spectrum which occupies a wider frequency space is generated by matching each spectrum in the overlapping area, and a synthetic object light wave hologram with increased numerical aperture is obtained thereby.Type: GrantFiled: July 31, 2018Date of Patent: May 9, 2023Assignee: University of HyogoInventor: Kunihiro Sato
-
Patent number: 11635289Abstract: The illumination light condensing point PQ and the reference light condensing point PL are arranged as mirror images of each other with respect to the virtual plane VP, and each data of the object light O, being a reflected light of the spherical wave illumination light Q, and the inline spherical wave reference light L is recorded on each hologram. On the virtual plane VP, the reconstructed object light hologram hV for measurement is generated, and the spherical wave optical hologram sV representing a spherical wave light emitted from the reference light condensing point PL is analytically generated. The height distribution of the surface to be measured of the object 4 is obtained from the phase distribution obtained by dividing the reconstructed object light hologram hV by the spherical wave light hologram sV.Type: GrantFiled: August 29, 2019Date of Patent: April 25, 2023Assignee: University of HyogoInventor: Kunihiro Sato
-
Publication number: 20230093066Abstract: The present invention provides a polarization-independent terahertz wave control element, and provides a method for manufacturing a polarization-independent terahertz wave control element.Type: ApplicationFiled: December 25, 2020Publication date: March 23, 2023Applicants: NAGAOKA UNIVERSITY OF TECHNOLOGY, UNIVERSITY OF HYOGO, NISSAN CHEMICAL CORPORATIONInventors: Tomoyuki SASAKI, Hiroshi ONO, Nobuhiro KAWATSUKI, Kohei GOTO, Kimiaki TSUTSUI
-
Patent number: 11560517Abstract: A photoreactive liquid crystal composition containing (A) a photoreactive polymer liquid crystal which includes a photoreactive side chain in which at least one type of reaction selected from (A-1) photocrosslinking and (A-2) photoisomerization occurs, and (B) a low molecular weight liquid crystal. An optical element or display element is formed having a liquid crystal cell including the photoreactive liquid crystal composition.Type: GrantFiled: July 7, 2020Date of Patent: January 24, 2023Assignees: UNIVERSITY OF HYOGO, NAGAOKA UNIVERSITY OF TECHNOLOGY, NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Tomoyuki Sasaki, Hiroshi Ono, Nobuhiro Kawatsuki, Kohei Goto
-
Patent number: 11541361Abstract: In order to provide a dispersion method and a dispersion apparatus capable of mixing a material to be processed and a dispersion medium having no affinity with each other using a single apparatus without using a dispersant, there are provided a quantitative supply mechanism quantitatively supplying a material to be processed, a suction stirring mechanism primarily including a suction stirring pump in which the material to be processed and a dispersion medium are subjected to negative pressure suction by a negative pressure suction force generated by rotation of a rotating blade and the suctioned material to be processed and the dispersion medium are stirred and mixed by the rotating blade and are allowed to pass through a throttle passage to cause cavitation, and a plasma generating mechanism generating a plasma in bubbles formed due to cavitation in a mixed liquid of the material to be processed and the dispersion medium.Type: GrantFiled: July 31, 2017Date of Patent: January 3, 2023Assignees: NIHON SPINDLE MANUFACTURING CO., LTD., UNIVERSITY OF HYOGO, KABUSHIKI KAISHA DAINICHI SEISAKUSHOInventors: Keiichi Asami, Yoshihiro Oka, Yoshimi Nishimura, Tomohiro Hashimoto, Katsuhiko Yonezawa
-
Patent number: 11492398Abstract: Based on the identification of IL-33 as an exacerbating factor in endometriosis and adenomyosis uteri, a therapeutic agent for endometriosis and adenomyosis uteri has an IL-33 antagonist, which is capable of inhibiting the function of IL-33. The IL-33 antagonist is useful for treating, preventing or alleviating endometriosis and uterine adenomyosis uteri.Type: GrantFiled: August 31, 2018Date of Patent: November 8, 2022Assignees: MITSUBISHI TANABE PHARMA CORPORATION, HYOGO COLLEGE OF MEDICINEInventors: Tomohiro Yoshimoto, Joseph M. Palumbo, Violetta I. Stone, Toru Kato, Koubun Yasuda
-
Publication number: 20220346651Abstract: A diseased person distinguishing device includes a temperature pattern calculation unit that calculates a temperature pattern in an exposed region of a subject on the basis of temperature data input from a body surface temperature measurement device that measures the body surface temperature of the subject, and a subject distinguishing unit that applies a learned model that has been learned in advance to the calculated temperature pattern to determine whether the subject is a diseased person or a healthy person.Type: ApplicationFiled: September 29, 2020Publication date: November 3, 2022Applicants: NIPPON AVIONICS CO., LTD., HYOGO COLLEGE OF MEDICINEInventors: Shoichi KIMURA, Kota MATSUMOTO, Yasushi UDA, Eijiro TANJI, Masahiro KOSHIBA, Hiromi SHIBATA, Osamu HORIE
-
Patent number: 11458445Abstract: Nanoparticles are synthesized by suctioning a liquid under a negative pressure with a negative-pressure suction force caused by the rotation of a rotary blade, causing cavitation by stirring the suctioned liquid by the rotary blade, generating plasma generated by a plasma generation mechanism in air bubbles generated in the liquid, and in that case, consuming an electrode containing elements constituting the nanoparticles to be synthesized.Type: GrantFiled: June 27, 2017Date of Patent: October 4, 2022Assignees: NIHON SPINDLE MANUFACTURING CO., LTD., UNIVERSITY OF HYOGOInventors: Keiichi Asami, Keiichiro Onishi, Yoshihiro Oka
-
Patent number: 11389486Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: July 11, 2019Date of Patent: July 19, 2022Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
-
Patent number: 11372326Abstract: The present disclosure relates to a pellicle that can achieve both a high EUV transmittance and a uniformity in EUV transmittance by including a graphite thin film having a film thickness of 5 nm or more and 30 nm or less and a surface roughness (Sa) of 0.1 nm or more and 500 nm or less.Type: GrantFiled: September 4, 2020Date of Patent: June 28, 2022Assignees: KANEKA CORPORATION, UNIVERSITY OF HYOGOInventors: Yuki Kawashima, Shuhei Ozaki, Masamitsu Tachibana, Takeo Watanabe, Tetsuo Harada
-
Patent number: 11246526Abstract: A swallowing diagnosis apparatus includes a controller which enables a first swallowing determination process of determining whether or not there is an aspiration risk in the swallowing on the basis of respiratory phases before and after a period in which swallowing has been estimated as having occurred; and a second swallowing determination process of extracting reference information including at least one of the sound information and the respiration information in a predetermined period including the period in which swallowing has been estimated as having occurred, obtaining a feature quantity from the extracted reference information, and performing a machine learning process on the obtained feature quantity to determine whether or not there is a possibility of dysphagia in the swallowing; and a display control process of causing a determination result obtained by the first swallowing determination process and a determination result obtained by the second swallowing determination process to be displayed.Type: GrantFiled: March 12, 2019Date of Patent: February 15, 2022Assignees: UNIVERSITY PUBLIC CORPORATION OSAKA, EuSense Medical Co., Ltd., HYOGO COLLEGE OF MEDICINE, J Craft Co., Ltd.Inventors: Michifumi Yoshioka, Katsufumi Inoue, Yoshitaka Oku
-
Publication number: 20200401038Abstract: The present disclosure relates to a pellicle that can achieve both a high EUV transmittance and a uniformity in EUV transmittance by including a graphite thin film having a film thickness of 5 nm or more and 30 nm or less and a surface roughness (Sa) of 0.1 nm or more and 500 nm or less.Type: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Applicants: KANEKA CORPORATION, UNIVERSITY OF HYOGOInventors: Yuki Kawashima, Shuhei Ozaki, Masamitsu Tachibana, Takeo Watanabe, Tetsuo Harada
-
Publication number: 20200338135Abstract: A lipocalin-type prostaglandin D2 synthase (L-PGDS) production promoting agent, more specifically an L-PGDS production promoting agent in pericytes or ischemia-induced multipotent stem cells (iSCs) dedifferentiated from pericytes. A substance having an L-PGDS production promoting action is contained in an extract from inflamed tissues inoculated with vaccinia virus. An L-PGDS production promoting agent is highly useful as a prophylactic, therapeutic or relapse prophylactic agent for a disease in which the effect by promotion of L-PGDS expression is expected to be effective, including a cerebrovascular disorder such as cerebral infarction, dementia such as Alzheimer's disease, or a sleep disorder.Type: ApplicationFiled: December 27, 2018Publication date: October 29, 2020Applicants: HYOGO COLLEGE OF MEDICINE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Tomohiro MATSUYAMA, Takayuki NAKAGOMI, Yu FUKUDA